In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Quantification of hypo-attenuated leaflet thickening after transcatheter aortic valve implantation - clinical relevance of HALT volume

Session Poster Session 4

Speaker Julia Karady

Event : ESC Congress 2019

  • Topic : imaging
  • Sub-topic : Computed Tomography: Valve Disease
  • Session type : Poster Session

Authors : J Karady (Budapest,HU), A Apor (Budapest,HU), AI Nagy (Budapest,HU), M Kolossvary (Budapest,HU), B Szilveszter (Budapest,HU), J Simon (Budapest,HU), L Molnar (Budapest,HU), A Bartykowszki (Budapest,HU), AL Jermendy (Budapest,HU), AL Panajotu (Budapest,HU), FI Suhai (Budapest,HU), AL Varga (Budapest,HU), R Rajani (London,GB), P Maurovich-Horvat (Budapest,HU), B Merkely (Budapest,HU)

J. Karady1 , A. Apor2 , A.I. Nagy2 , M. Kolossvary1 , B. Szilveszter1 , J. Simon1 , L. Molnar2 , A. Bartykowszki1 , A.L. Jermendy1 , A.L. Panajotu1 , F.I. Suhai1 , A.L. Varga2 , R. Rajani3 , P. Maurovich-Horvat1 , B. Merkely1 , 1Semmelweis University, Cardiovascular Imaging Research Group, Heart and Vascular Center - Budapest - Hungary , 2Semmelweis University, Heart and Vascular Center - Budapest - Hungary , 3St Thomas' Hospital, Department of Cardiology - London - United Kingdom ,

On behalf: Cardiovascular Imaging Research Group, Semmelweis University, Budapest, Hungary

European Heart Journal ( 2019 ) 40 ( Supplement ), 2003

Background: Hypo-attenuated leaflet thickening (HALT) is a recently recognized phenomenon following transcatheter aortic valve implantation (TAVI) and there is no consensus over the standardized assessment of HALT and its clinical relevance is poorly understood. We sought to determine the predictors and clinical significance of HALT volume.

Methods: Patients, who previously underwent TAVI between 2011 and 2016 were prospectively enrolled in the RETORIC (Rule out Transcatheter Aortic Valve Thrombosis with Post Implantation Computed Tomography) study, a single-center observational study. At inclusion cardiac computed tomography angiography (CTA), transthoracic echocardiography (TTE) and brain magnetic resonance imaging (MRI) was performed. HALT was volumetrically quantified on cardiac CTA images by segmenting the inner volume of the TAVI frame at the level of the leaflets and applying a threshold of −200 to 200 Hounsfield units. We evaluated the clinical predictors of HALT volume, and its association with ischemic brain MRI lesions (recent and chronic large vessel ischemic focuses, microbleed/microembolization, white matter or small vessel disease) and all-cause mortality.

Results: In total, we analyzed 111 patients with CoreValve bioprosthesis (56.7% female, mean age 80.3±7.4 years). A median of 19 [IQR: 11–29] months passed between TAVI procedure and enrollment. The mean HALT volume was 111.0±163.4 mm3. Current malignant disease, prosthesis implantation depth measured on CTA images acquired at inclusion, and aortic mean gradient and aortic valve area evaluated on TTE images at inclusion predicted HALT volume by univariate analysis (all p<0.05). After multivariate adjustment, aortic mean gradient remained a significant predictor of HALT volume (beta-coefficient: 11.5, 95% CI: 5.0–18.0; p<0.001). HALT volume was not associated with ischemic brain MRI lesions (all p>0.05) and did not predict all-cause mortality (median follow-up: 20 months [IQR: 18–23]; HR: 1.0; 95% CI: 1.0–1.0; p=0.15).

Conclusion: Aortic mean gradient was the only predictor independently associated with HALT volume. Our results suggest that TAVI valve function is negatively affected by HALT volume, however, we found no association of HALT volume with cerebrovascular ischemic lesions or increased risk for all-cause mortality.

Volumetric quantification of HALT.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are